FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to experimental oncological ophthalmology, and can be used for treating malignant eye socket tumours in experiment in mice with transplanted intraocular Ehrlich carcinoma. For this purpose, compound 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol is used in a single dose of 20 mg/kg intraperitoneally.
EFFECT: use of compound 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol increases the therapeutic effect in the treatment of mice with transplanted intraocular Ehrlich carcinoma, promotes inhibition of tumour growth and prolongation of life with complete recovery.
1 cl, 7 dwg, 4 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
APPLICATION OF COMPOUND 2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1.3-PROPANEDIOL FOR TREATMENT OF EHRLICH CARCINOMA, SARCOMA 37, LIO-1 LYMPHOSARCOMA, MELANOMA B16, TRANSPLANTED INTO LOWER EYELID OF MICE IN EXPERIMENT | 2020 |
|
RU2752083C1 |
USE OF THE COMPOUND 2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1,3-PROPANEDIOL ORALLY FOR THE TREATMENT OF MELANOMA B16, EHRLICH TUMOR, SARCOMA 180, SARCOMA 37, LYMPHOSARCOMA LIO-1 AND CARCINOSARCOMA WALKER 256 EXPERIMENTALLY IN MICE AND RATS | 2020 |
|
RU2733643C1 |
USE OF THE COMPOUND 2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1,3-PROPANEDIOL FOR TREATING HER2-POSITIVE TUMORS EXPERIMENTALLY | 2018 |
|
RU2695787C1 |
METHOD OF SYNTHESIS 2-[3-(2-CHLORETHYL)-3-NITROSOUREIDO]-1,3-PROPANE-DIOL OWNED WITH ANTITUMOR ACTIVITY | 2018 |
|
RU2678846C1 |
2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1,3-PROPANEDIOL SHOWING ANTITUMOR ACTIVITY | 1992 |
|
RU2068843C1 |
5-OXYMETHYL-5-[3-(2-CHLORETHYL)-3- NITROZOUREIDO]-2-CYCLOHEXYL- 1 | 2000 |
|
RU2179555C1 |
INDOL-3-CARBOXIC ACID DERIVATIVES WITH ANTI-TUMOR ACTIVITY | 2022 |
|
RU2782931C2 |
DIHYDROCHLORIDE 1-(3-NITRO-4- METHOXYBENZENE)-2- [BIS-(2- CHLORETHYL) AMINOMETHYL]IMIDAZOLE POSSESSING ANTITUMOR ACTIVITY | 1981 |
|
SU976654A1 |
2-BIS-(β- CHLOROETHYL)- AMINO- OR 2-PHENOXY -5,7-DIMETHYL -2,6-DIOXO- 1,3-DIAZA -2-PHOSPHAADAMANTANES SHOWING ANTITUMOR ACTIVITY | 1985 |
|
SU1282521A1 |
COMPLEX ANTI-TUMORAL PRODUCT | 2020 |
|
RU2751776C2 |
Authors
Dates
2024-03-19—Published
2023-07-11—Filed